Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 18: Perindopril - Koronarreserve Abb. 19: Perindopril - Fibrinolyse Abb. 20: Perindopril - Antiatheriosklerotischer Effekt Aktuelles Bild - Abb. 21: Perindopril - Antiischämische Wirksamkeit Abb. 22: Perindopril - Verträglichkeit Abb. 23: Perindopril - Verträglichkeit Abb. 24: EUROPA-Studie - Studienziel Zum letzten Bild
Abbildung 21: Perindopril - Antiischämische Wirksamkeit
Finally and as a final proof of perindopril’s choice for EUROPA it is interesting to look after its anti-ischemic efficacy, as recently proven in humans suffering from stable angina. After 3 months of treatment, perindopril given at the same dosage as used in EUROPA, that is to say 8 mg significantly reduces the time to ST-segment depression, as well as exercise-induced left ventricular systolic dysfunction. A linear relationship exists between the inhibition of plasma ACE by perindopril and the increase in bradykinin concentration. This high concentration is thought to be involved in the anti-ischaemic effects obtained with perindopril. This further emphazises its choice to conduct the EUROPA trial.
 
Perindopril - Antiischämische Wirksamkeit
Vorheriges Bild Nächstes Bild   


Abbildung 21: Perindopril - Antiischämische Wirksamkeit
Finally and as a final proof of perindopril’s choice for EUROPA it is interesting to look after its anti-ischemic efficacy, as recently proven in humans suffering from stable angina. After 3 months of treatment, perindopril given at the same dosage as used in EUROPA, that is to say 8 mg significantly reduces the time to ST-segment depression, as well as exercise-induced left ventricular systolic dysfunction. A linear relationship exists between the inhibition of plasma ACE by perindopril and the increase in bradykinin concentration. This high concentration is thought to be involved in the anti-ischaemic effects obtained with perindopril. This further emphazises its choice to conduct the EUROPA trial.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung